Sanofi and its vaccines global business unit, Sanofi Pasteur, have provided 500,000 doses of Dengvaxia, a dengue vaccine, to the state of Paraná in Brazil to support a large-scale public dengue-immunization program that was recently initiated there.

The safety, efficacy, and public health value of the dengue vaccine has been independently endorsed by the World Health Organization in July 2016. In addition to Brazil, the vaccine is also registered in Mexico, Philippines, El Salvador, and Costa Rica to date. Regulatory review processes for the dengue vaccine are continuing in other countries where dengue is a public health priority.

Sanofi Pasteur said it will continue to address all supply demands coming from all clinics in Brazil, both public and private, as well as any additional requests from other countries supported by the company's ample dengue vaccine supply capacity from its production facility in France.

Source: Sanofi